NHS National Generic Pharmaceuticals Transition 2021_1

Tender description

Transition and 33 % products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months). Lot 01: Transition 2021_1 - 100% Products (All regions) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments Lot 02: Transition 2021_1 - CESW region (Transition & 33% products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments Lot 03: Transition 2021_1 - LSNE region (Transition & 33% products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Lot 04: Transition 2021_1 - NWLN region (Transition & 33% products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments